5 research outputs found
Similar cellular responses after treatment with either praziquantel or oxamniquine in Schistosoma mansoni infection.
The effect of treatment with either oxamniquine or praziquantel on S.mansoni specific IFN-gamma, IL-4, IL-5 and IL-10 was compared on PBMC which were collected pretreatment, 6 and 18 weeks post treatment. Using sandwich ELISA on the supernatants harvested from the PBMC stimulation by crude S. mansoni SEA and SWAP antigens after 5 days the levels of PBMC proliferation and cytokine production were similar according to treatment with either praziquantel or oxamniquine. Before treatment, infected groups showed low ratios, of IL-4:IFN-gamma, IL-5:IFNgamma and IL-10:IFN-gamma, indicating that IFN-gamma was high in the infected individuals. The general increase in immuno-modulation was observed post-treatment with elevated immune reactivity and cytokine production in both treatment groups. Treatment induced significant increases in levels of IL-4 (p < 0.05), IL-5 (p < 0.0001) and IL-10 (p < 0.05) cytokines 6 and 18 weeks after treatment. There were no significant differences in the increase in IL-4, IL-5 and IL-10 between children treated with praziquantel or oxamniquine. Pre-treatment IFN-gamma and IL-5 levels were positively correlated with infection (p < 0.001), while post treatment IL-4 cytokine levels were negatively correlated with baseline infection status (p < 0.001). The results suggest that treatment-induced immune responses are similar for both common anti-schistosome drugs praziquantel or oxamniquine having similar and immunizing effect
Similar cellular responses after treatment with either praziquantel or oxamniquine in Schistosoma mansoni infection.
The effect of treatment with either oxamniquine or praziquantel on
S.mansoni specific IFN-gamma, IL-4 , IL-5 and IL-10 was compared on
PBMC which were collected pre-treatment, 6 and 18 weeks post treatment.
Using sandwich ELISA on the supernatants harvested from the PBMC
stimulation by crude S. mansoni SEA and SWAP antigens after 5 days
the levels of PBMC proliferation and cytokine production were similar
according to treatment with either praziquantel or oxamniquine. Before
treatment, infected groups showed low ratios, of IL-4:IFN-gamma,
IL-5:IFN-gamma and IL-10:IFN-gamma, indicating that IFN-gamma was high
in the infected individuals. The general increase in immuno-modulation
was observed post-treatment with elevated immune reactivity and
cytokine production in both treatment groups. Treatment induced
significant increases in levels of IL-4 (p<0.05), IL-5 (p<0.0001)
and IL-10 (p<0.05) cytokines 6 and 18 weeks after treatment. There
were no significant differences in the increase in IL-4, IL-5 and IL-10
between children treated with praziquantel or oxamniquine.
Pre-treatment IFN-gamma and IL-5 levels were positively correlated with
infection (p<0.001), while post treatment IL-4 cytokine levels were
negatively correlated with baseline infection status (p<0.001). The
Results suggest that treatment-induced immune responses are similar for
both commonanti-schistosome drugs praziquantel or oxamniquine having
similar and immunizing effect